Emmecell
Noelia Kunzevitzky, PhD, currently serves as the Chief Operating Officer and Director of Operations at Emmecell, where efforts focus on developing a cell therapy aimed at treating corneal edema since December 2011. In addition, Noelia is a Co-Founder of CellMP, active since August 2018. Noelia's prior experience includes a role as Quality & Regulatory Affairs Manager at Promedon SA from June 2000 to February 2004. Noelia received a PhD from the Bascom Palmer Eye Institute at the University of Miami in 2009 and completed a postdoctoral program in Bioinformatics at the same university in 2011. An undergraduate degree in Biochemistry and Clinical Chemistry was earned from Universidad Nacional de Córdoba in 2002.
This person is not in any teams
Emmecell
Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation. Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA.